Psychiatry Research
October 1, 2023
François A M Jean, Ashlyn N Schwartz, Charline Galesne et al.
3 citations
In a cross sectional study of 13,837 university students, we aimed to explore the association between attention deficit hyperactivity disorder (ADHD) symptoms and lifetime psychoactive substance use (LPSU) on a wide range of illicit substances. Logistic and Hurdel multivariable regressions were used. ADHD symptoms were significantly associated with the lifetime use of ketamine, magic mushrooms,...
bioRxiv (Cold Spring Harbor Laboratory)
September 26, 2023
Yi-Ting Chiu, Wei Wang, Pierre Llorach et al.
15 citations
preprint
ABSTRACT Psychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin have emerged as potentially transformative therapeutics for many neuropsychiatric diseases, including depression, anxiety, post-traumatic stress disorder, migraine, and cluster headaches. LSD and psilocybin exert their psychedelic effects via activation of the 5-hydroxytryptamine 2A receptor (HTR2A). Here we provide...
Revista Ibero-Americana de Humanidades, Ciências e Educação
September 22, 2023
Júlia Ruys Mattos Queiroz da Silva, Marcos Antônio Mendonça
2 citations
Este trabalho apresenta uma análise sobre a terapia psicodélica como uma possível abordagem para tratamentos psiquiátricos, visando a saúde mental, explorando suas raízes históricas, fundamentos neurobiológicos e resultados clínicos. A revisão da literatura revela que substâncias psicodélicas, como a psilocibina e o MDMA (ecstasy), demonstram um potencial terapêutico promissor para transtornos...
Kybernetes
September 21, 2023
Kip Errett Patterson
Purpose The purpose of this conceptual paper is to demonstrate how memes perpetuate trauma with a schematic. This conceptual paper uses the “begin with the end in mind” meme to format the presentation of the necessary components for the schematic of how trauma persists across generations. It is the third paper in a series of applications of the recursive, test-operate-test schematic to the...
Frontiers in Psychiatry
September 20, 2023
Taylor Black
2 citations
Psychedelic-assisted treatment (PAT) for mental health is in renaissance. Psilocybin and MDMA stand near FDA approval, and US cities and states are decriminalizing or regulating the non-clinical use of psilocybin. However, neither FDA indications nor a regulated use model sufficiently address the complex needs and opportunities for an improved treatment of addiction. When paired with disability...
ACS Pharmacology & Translational Science
September 18, 2023
Richa Tyagi, Tanishka S. Saraf, Clinton E. Canal
5 citations
The serotonergic psychedelic psilocybin shows efficacy in treating neuropsychiatric disorders, though the mechanism(s) underlying its therapeutic effects remain unclear. We show that a similar psychedelic tryptamine, N,N-dipropyltryptamine (DPT), completely prevents audiogenic seizures (AGS) in an Fmr1 knockout mouse model of fragile X syndrome at a 10 mg/kg dose but not at lower doses (3 or...
World Psychiatry
September 15, 2023
Daniel Souery
2 citations
convincing phase 3 programme leading to eventual approval of psilocybin as a medicine.We are not there yet.
ACS Medicinal Chemistry Letters
September 15, 2023
Robert B. Kargbo
11 citations
Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has granted "breakthrough therapy designation" to psilocybin and MDMA for treatment-resistant depression, major depressive disorder, and post-traumatic stress disorder, sparking global research efforts. Various clinical trials are currently investigating...
Journal of Community Safety and Well-Being
September 14, 2023
Renae M. Stevenson
The setting of policing exposes its officers to a host of negative health outcomes physiologically, psychologically, and spiritually. Policing mindsets around accessing mental health are far from fixing the epidemic of its mental health crisis or being able to sustain a healthy workforce. Policing is losing the battle with a misguided and a scientifically misinformed war on drugs. Canadian...
American Journal of Psychiatry Residents Journal
September 8, 2023
Lawrence Canale, Dhvanit Raval, Preet Chatha et al.
Psychedelics as therapeutic agents have generated significant attention from clinicians and media sources in recent years. The authors provide an update to the psychiatric trainee on the evidence for psychedelics in the treatment of major depressive disorder and treatment-resistant depression. Many modern clinical trials of the classic, serotonergic psychedelics, such as psilocybin, ayahuasca,...